Peipei Lu

Peipei Lu has a diverse work experience in scientific research. They started their career as a Research Assistant at Xi'an Jiaotong University from January 2008 to June 2011. They then became an Immunology Intern at Genentech in June 2015, where they developed and validated an immune-PCR assay platform for detecting a specific protein in asthma patients.

In September 2011, Peipei Lu joined the University of Pittsburgh as a Research Assistant in Cellular and Molecular Biology. During their time there, they investigated the endobiotic and hepatic function of the aryl hydrocarbon receptor (AHR) in metabolic diseases and hepatocellular carcinoma. They engineered humanized AHR transgenic mice and established the endocrine hormone FGF21 as a target of AHR. They also verified the role of FGF21 in AHR-induced hepatic and endobiotic phenotype.

From September 2016 to January 2021, Peipei Lu served as a Postdoctoral Researcher in Cancer Genomics at Stanford University. They studied transcriptome and genome evolution during HER2-amplified breast neoplasia and analyzed the clonal relationship in precancer lesions at a single duct level. They also examined changes in oncogenic signaling and detected the activation of interferon signaling by HER2 amplification.

Most recently, starting in May 2022, Peipei Lu is working as a Scientist II at GRAIL. The specific roles and responsibilities in this position are not provided.

Peipei Lu completed their Bachelor's degree in Pharmacy at Xi'an Jiaotong University from 2004 to 2008. peipei then went on to pursue a Master's degree in Pharmacology at Xi'an Jiaotong University from 2008 to 2011. Finally, they completed their education with a Doctor of Philosophy (PhD) in Cell/Cellular and Molecular Biology at the University of Pittsburgh from 2011 to 2016.